Spect
YC S17 · Inactive · Value-based retinal screening in primary care to prevent blindness.
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
| AI | Not stated | EF2017 | |
| Other | Inactive | YCW16 | |
| AI | Inactive | YCW21 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
| Other | Acquired | YCW15 | |
| Other | Active | YCW19 | |
| Other | Inactive | YCS21 | |
| Other | Inactive | YCS20 | |
| Other | Active | YCW21 |
Also from S17 in AI
All of S17About Spect
Vision Disease cause innumerable cases of preventable blindness globally - 415 million diabetic patients worldwide are susceptible to Diabetic Retinopathy (DR), Glaucoma, and more. Current screening protocols for vision disease require ophthalmologists to manually diagnose patients through visual assessment of the fundus. Given the large number of diabetes patients in various communities, this process is expensive, inefficient, and an undue burden on eye clinics.
- YC batch
- S17 · Summer 2017
- Status, per YC
- Inactive
- Category
- AI
- Team size
- 7
- Location
- San Francisco, CA, USA; Palo Alto, CA, USA; Remote
- Checked
- 31m ago
YC tags: Digital Health, AI
Spect: questions
Which YC batch was Spect in?
Spect was in Y Combinator's Summer 2017 batch (S17).
Is Spect still active?
Y Combinator lists Spect as inactive.
Where is Spect based?
Spect lists San Francisco, CA, USA; Palo Alto, CA, USA; Remote as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.